At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 18, 2026 at 07:00 ET
Arvinas presented positive Phase 1 data for ARV-102, showing approximately 50% or greater reduction of LRRK2 in cerebrospinal fluid in Parkinson’s patients, with good tolerability and biomarker improvements. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy (PSP) in Q2 2026, pending regulatory feedback, supporting further development in neurodegenerative diseases.
- ARV-102 achieved ≥50% LRRK2 reduction in CSF by day 14 and sustained through day 28 across all dose levels (20–80 mg) in Parkinson’s patients
- ARV-102 demonstrated dose-dependent brain penetration and reduction of endolysosomal and neuroinflammatory biomarkers (e.g., CD68, GPNMB)
- No serious adverse events (SAEs) were reported; drug was well tolerated over 28 days
- Arvinas plans to initiate a Phase 1b trial in PSP in Q2 2026, with potential registrational trial by late 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access